Tenofovir exerts antiviral effects in pregnant women with chronic hepatitis B by influencing the expression of miR ‐21‐5p
Journal of Obstetrics and Gynaecology Research · 2025
DOI: 10.1111/jog.16355 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2025. Verfasst von Lei Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Shijiazhuang Maternal and Child Health Hospital, Shijiazhuang, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, MicroRNAs, Tenofovir, Antiviral Agents. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Hebei Provincial Health Care Commission.
Abstract (Originalsprache)
Objective
In pregnant women with chronic hepatitis B (CHB), tenofovir (TDF) has demonstrated significant efficacy in disrupting the replication of the hepatitis B virus (HBV) and in preventing mother‐to‐child transmission (MTCT). This study seeks to elucidate the role of miR‐21‐5p in mediating the antiviral effect of TDF.
Methods
Initially, the levels of miR‐21‐5p in pregnant women with and without CHB were compared by RT‐qPCR assay. Subsequently, a comparison was made between the levels of HBV and miR‐21‐5p prior to and following treatment with TDF. Moreover, the correlation between miR‐21‐5p levels and HBV DNA, HBsAg or HBeAg was analyzed by Pearson correlation analysis. Lastly, HBV‐infected huh‐7 cells were cultured in vitro. Then, RT‐qPCR and ELISA assays were conducted to investigate the influence of modulating miR‐21‐5p levels on HBV replication. Results miR‐21‐5p levels were significantly increased in CHB pregnant women. Following treatment with TDF, HBV was effectively controlled. More crucially, TDF led to a reduction in miR‐21‐5p levels. The level of miR‐21‐5p exhibited a positive correlation with HBV DNA, HBsAg and HBeAg. In cell experiments, the inhibition of miR‐21‐5p resulted in a significant decrease in levels of HBV DNA, HBsAg, and HBeAg. Conversely, overexpression of miR‐21‐5p yielded opposing results.
Conclusion
In pregnant women with CHB, TDF may inhibit HBV replication by inhibiting the expression of miR‐21‐5p. This mechanism contributes to the mitigation of infection exacerbation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Shijiazhuang Maternal and Child Health Hospital, Shijiazhuang, China.
ORCID-Profile: Jinyu Gu
Förderung
- Hebei Provincial Health Care Commission
Zitieren
APA
Zhang, L., Du, J., Shao, L., Yang, C., Wang, Y., Mo, Z., & Gu, J. (2025). Tenofovir exerts antiviral effects in pregnant women with chronic hepatitis B by influencing the expression of miR ‐21‐5p. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.16355
Vancouver
Zhang L, Du J, Shao L, Yang C, Wang Y, Mo Z, et al. Tenofovir exerts antiviral effects in pregnant women with chronic hepatitis B by influencing the expression of miR ‐21‐5p. Journal of Obstetrics and Gynaecology Research. 2025. doi:10.1111/jog.16355
BibTeX
@article{Zhang2025,
author = {Zhang, Lei and Du, Juan and Shao, Lan and Yang, Cuili and Wang, Yu and Mo, Zhongfu and Gu, Jinyu},
title = {Tenofovir exerts antiviral effects in pregnant women with chronic hepatitis B by influencing the expression of miR ‐21‐5p},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2025},
doi = {10.1111/jog.16355}
}
EUVIMED